Human Corneal Epithelial Sheet Production via Amnion Substrate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human corneal epithelial sheets face challenges in achieving stable quality and efficiency, particularly due to donor shortages and inflammation issues during transplantation, and existing techniques require improvement in producing sheets with consistent quality and reduced rejection rates.
Innovation Solution
A method involving the culture of human corneal epithelial cells using mesenchymal stem cells as feeder cells with specific inhibitors (ROCK, phosphodiesterase, MAP kinase, and TGF-β receptor inhibitors) in a medium, allowing for efficient production of corneal epithelial sheets on an amnion substrate, which are then transplanted to address corneal diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human corneal epithelial cells are cultured using conventional methods, then cell sheets can be produced, but the quality is unstable and rejection rates are high
Solution Approach 1:
The patent introduces amnion membrane as an intermediary substrate for cell culture. The amnion membrane serves as a mediator between the culture medium and the corneal epithelial cells, providing a biocompatible surface that enhances cell attachment and sheet formation while reducing immune rejection during transplantation
Solution Approach 2:
The patent modifies culture conditions by adding specific growth factors (EGF, bFGF, IGF-1) and adjusting medium composition to optimize cell proliferation and differentiation. These parameter changes in the culture environment enable consistent production of high-quality epithelial sheets with stable characteristics
2Reliability
If corneal epithelial stem cells are used for transplantation, then barrier functions can be restored, but donor shortage limits availability
Solution Approach 1:
The patent performs preliminary expansion of corneal epithelial cells in vitro before transplantation. By culturing and multiplying the cells ex vivo, the method prepares sufficient cell numbers for transplantation without requiring additional donor tissues, thereby overcoming the donor shortage limitation
Solution Approach 2:
The patent creates artificial copies of corneal epithelial tissue through cell culture on amnion membrane. Instead of relying on natural donor tissues, the method reproduces functional corneal epithelium in the laboratory setting, providing unlimited supply of transplantable tissue with consistent quality
3Object-affected harmful factors
If cell sheets are formed on amnion substrate, then inflammation is suppressed, but production efficiency needs improvement
Solution Approach 1:
The patent implements continuous cell culture and sheet formation processes on amnion substrate. By maintaining continuous growth conditions and optimizing culture time, the method achieves both anti-inflammatory benefits and improved production efficiency through uninterrupted cell proliferation and sheet maturation
Data Source
AI summary
[Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate.[Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF-β receptor inhibitor in various combinations.